NMA后短程Tacro联合高剂量移植后Cy用于难植入恶性肿瘤的亲缘供者PBSCT
该数据集来自clinicaltrials.gov,聚焦于一组难植入的恶性血液肿瘤患者,涵盖骨髓增生异常综合征、慢性粒单核细胞白血病、小淋巴细胞淋巴瘤、慢性淋巴细胞白血病、幼淋巴细胞白血病、慢性髓性白血病、慢性骨髓增殖性疾病和多发性骨髓瘤

基本信息
资源简介
NMA后短程Tacro联合高剂量移植后Cy用于难植入恶性肿瘤的亲缘供者PBSCT
该数据集来自clinicaltrials.gov,聚焦于一组难植入的恶性血液肿瘤患者,涵盖骨髓增生异常综合征、慢性粒单核细胞白血病、小淋巴细胞淋巴瘤、慢性淋巴细胞白血病、幼淋巴细胞白血病、慢性髓性白血病、慢性骨髓增殖性疾病和多发性骨髓瘤。其核心目标是探究在非清髓性造血干细胞移植后,使用高剂量移植后环磷酰胺方案时,免疫抑制剂他克莫司能否以比既往更短的疗程安全给药。由于其他异基因移植平台的经验无法直接外推至此方案,且目前缺乏关于他克莫司最短必要疗程的已发表数据,该数据可用于分析移植后免疫抑制时长与安全性、并发症及植入效果之间的关联,支持临床预测与治疗策略优化(来源 clinicaltrials.gov)。
【数据内容】
源站描述(机器翻译,仅供参考):疾病:骨髓增生异常综合征、慢性粒单核细胞白血病、小淋巴细胞淋巴瘤、慢性淋巴细胞白血病、幼淋巴细胞白血病、慢性髓性白血病、慢性骨髓增殖性疾病、多发性骨髓瘤。主要目标是了解一种名为他克莫司的药物,这是一种免疫抑制药物(免疫抑制剂),在移植后给予以帮助预防某些并发症,能否以比过去更短的疗程安全给药。其他异基因HSCT平台的免疫抑制持续时间经验不能直接外推到高剂量移植后环磷酰胺平台(另一种在移植后给予以帮助预防GVHD的免疫抑制剂)。目前尚无关于包含高剂量Cy的非清髓性HSCT后他克莫司最短必要疗程的已发表数据。
【主题与分类】
主题标签:Myelodysplastic Syndrome、Chronic Myelomonocytic Leukemia、Small Lymphocytic Lymphoma、Chronic Lymphocytic Leukemia、Prolymphocytic Leukemia、Chronic Myeloid Leukemia、Chronic Myeloproliferative Disorders、Multiple Myeloma、Plasma Cell Neoplasm、Plasma Cell Dyscrasia。本站分类:肿瘤/白血病。
【获取与许可】
源站页面:https://clinicaltrials.gov/study/NCT02556931
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取
源站:https://clinicaltrials.gov/study/NCT02556931
标准获取流程:
- 访问源站链接,注册/登录账号;
- 进入数据集详情页,按页面指引申请权限或直接下载;
- 部分平台提供 SDK,例如:
- OpenDataLab:
pip install openxlab后openxlab.dataset.get(...) - ModelScope:
pip install modelscope后modelscope download - 天池: 登录后页面提供直链下载
以源站「数据下载/使用文档」页面为准。
- OpenDataLab:
数据说明
Conditions: Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myeloproliferative Disorders, Multiple Myeloma. The main goal is to learn whether a drug called tacrolimus, which is an immune-lowering drug (an immunosuppressant) given after transplant to help prevent certain complications, can be given safely for a shorter period of time than it has been in the past. The experiences with immunosuppression duration with other allogeneic HSCT platforms cannot be directly extrapolated to the high-dose posttransplantation cyclophosphamide platform (another type of immunosuppressant given after transplant to help prevent GVHD). There are presently no published data on the minimum required duration of tacrolimus after nonmyeloablative HSCT that includes high-dose Cy as part of postgrafting immunosuppression. The effectiveness of high-dose posttransplantation Cy in GVHD prevention, however, permits the investigation of this question. At the present time there are few or no cures for diseases studied on this trial outside of a bone marrow or peripheral blood transplant. The peripheral blood for this transplant comes from a relative who is a half-match or “haplo” match to the participant. Possible donors include parents, siblings, and children. In order to help the bone marrow grow, or “take”, inside the body, participants will receive chemotherapy and radiation before the transplant. After the transplant participants will receive high doses of cyclophosphamide (Cytoxan®) along with other medications to lower the immune system, such as tacrolimus. These medications may lower the risk of graft versus host disease (GVHD) and of rejection of the peripheral blood graft.
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




